| Product | Indication | Dosage form | Strength |
|---|---|---|---|
| Risperidone | Psychosis, schizophrenia, bipolar disoder | Film-coated tablets | 1, 3 and 6 mg |
| Rivaroxaban | Thrombosis, stroke | Film-coated tablets | 10, 15 and 20 mg |
| Rizatriptan | Migraine | Orodispersable tablets | 5 and 10 mg |
| Rotigotine | Parkinson disease & restless legs | Patches | 1, 2, 3, 4, 6 and 8 mg/24h |
| Seripnol® | Useful to promote relaxation and sleep | Mar 2012 | |
| Seripnol® drops | Useful to promote relaxation and sleep | Apr 2014 |
|
| Sodium Oxybate | Narcolepsy | Oral solution | 500 mg/ml |
| Solifenacin | Overactive bladder, urinary incontinence | Film-coated tablets | 5 and 10 mg |
| Sulpiride | Psychosis, schizophrenia | Tablets | 50 and 200 mg |
| Sultiame * | Epilepsy, convulsions | Film-coated tablets | 50, 100 and 200 mg |
| Telmisartan | Hypertension | Tablets | 20, 40 and 80 mg |
| Tolcapone | Parkinson's | Film-coated tablets | 100 mg |
| Tranylcypromine | Depression | Film-coated tablets | 10, 20 and 40 mg |
| Tranylcypromine | Depression | Film-coated tablets | 10, 20 and 40 mg |
| Trazodone | Depression | XR tablets | 75 and 150 mg |
| Triadenor® | Useful for the management of depressive disorders | Nov 2014 | |
| Trimipramine | Depression | Oral drops, solution | 40mg / ml |
| UMP + Folic Acid + B12 | Useful for the treatment of spinal syndromes, neuralgias and polyneuropathies | Jul 2018 | |
| Valproate | Epilepsy | Oral solution | 300mg/ ml (100ml) 300mg/ 5ml (250ml) |
| Valsartan | Hypertension | Film-coated tablets | 40, 80, 160 and 320 mg |
[*] Differentiated product
[**] Opioid
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.